Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma Leronlimab ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a ...

Erythema multiforme (EM) represents a spectrum of acute, immune-mediated mucocutaneous conditions that predominantly affect the skin and, in many instances, the oral mucosa. Typically presenting with ...

Glioblastoma multiforme (GBM) is the most common and aggressive type of tumor arising from star shaped cells called as astrocytes that make up supportive tissue of the brain. GBM has long baffled ...

A study led by Nicolas Bazan, MD, Ph.D., Boyd Professor and Director of LSU Health New Orleans Neuroscience Center of Excellence, reports that in an experimental model of glioblastoma multiforme (GBM) ...

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global Glioblastoma Multiforme (GBM) ...

A 35-year-old woman presented to the emergency department with a recurrent rash on the backs of both hands related to what she described as a “fever blister” on her lower lip. In the previous 2 years, ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

A NUMBER of reports have appeared in the literature in recent years on the condition known as the Stevens-Johnson syndrome. The numerous descriptive names attached to its multiple manifestations have ...

Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Mean progression-free survival is just over 6 months; treatment with surgical resection, chemotherapy, and radiation ...